論文

査読有り
2004年11月

Novel prophylactic effect of doxifluridine in superficial bladder cancer

SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
  • H Matsuyama
  • ,
  • Y Baba
  • ,
  • T Shimabukuro
  • ,
  • K Uchiyama
  • ,
  • A Aoki
  • ,
  • A Suga
  • ,
  • K Jojima
  • ,
  • K Suyama
  • ,
  • N Yamamoto
  • ,
  • K Naito

38
5
開始ページ
366
終了ページ
372
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1080/00365590410033425
出版者・発行元
TAYLOR & FRANCIS AS

Objectives: The prophylactic effect of 5'-deoxy-5-fluorouridine (5'-DFUR) has not been fully studied in superficial bladder cancer. The aims of this work were to investigate the prophylactic effects of 5'-DFUR in terms of tumor recurrence after transurethral resection of bladder tumor (TURBT) and to study whether thymidine phosphorylase (TdRPase) immunostaining predicts tumor recurrence.
Material and Methods: A total of 112 patients with pTa or pT1 bladder cancer were eligible for the analysis and were allocated to either an adjuvant group (TURBT + 5'-DFUR; n = 47; initial 23 months) or a control group (TURBT alone; n = 65, final 23 months). Tumor specimens were studied immunohistochemically using anti-TdRPase antibody.
Results: Tumor recurrence was observed in 54 of the patients (48%) after a median follow-up period of 26.8 months. No significant clinico-pathologic bias was observed between the two groups. Although patients in the adjuvant group had a significantly higher recurrence-free survival rate than those in the control group when considering 78 patients with pathological T1 tumors ( p = 0.0272) and 65 patients who did not recur within 12 months ( p = 0.001), overall there was no significant difference between the two groups. Multivariate analysis revealed that 5'-DFUR administration was the strongest predictor of late tumor recurrence, which was defined as development of recurrence 12 months after TURBT ( hazard ratio 5.744; 95% CI 1.495 - 30.45; p = 0.0094). Immunostaining did not predict prophylactic effects of 5'-DFUR. Mild, reversible toxicity was found in 9/58 (15.5%) of the cases evaluated.
Conclusions: Oral administration of 5'-DFUR after TURBT did not prevent tumor recurrence in the overall cohort, although this novel drug may have a prophylactic effect in patients belonging to several subgroups.

リンク情報
DOI
https://doi.org/10.1080/00365590410033425
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/15764246
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000225091000002&DestApp=WOS_CPL
ID情報
  • DOI : 10.1080/00365590410033425
  • ISSN : 0036-5599
  • PubMed ID : 15764246
  • Web of Science ID : WOS:000225091000002

エクスポート
BibTeX RIS